CD4 and ovarian carcinoma: The CTA NY-ESO-1, a homologous family member of TMEFF1, can induce a higher antibody titer and CD4+/CD8+ T cell immune response, with a vaccine treatment prolonging the progression-free survival of patients with advanced ovarian cancer.